By Elric Langton | 8th December 2021
I am sensing Synairgen Plc (LSE: SNG), a respiratory company focused on drug discovery, development and company, whose primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs β¦